latest news releases from the newsroom
Ten Years of Strategic Streamlining: Sales Up 45%, Exports Rise 20%, Workforce Expands
GOTEBORG, Sweden, June 07, 2004 (PRIMEZONE) -- Ten years after Volvo (Nasdaq:VOLVY) (Other OTC:VOLVF) (Other OTC:VOLAFK) began to streamline its operations around its automotive operations and five years after the sale of Volvo Cars to Ford, the Volvo Group is now a considerably larger and stronger company. Both sales and exports have risen substantially since 1993. Even the workforce is larger. At the same time, Volvo Cars has developed well and has increased its sales markedly.
IBS Wins Order in Denmark Worth SEK 16 Million
STOCKHOLM, Sweden, June 07, 2004 (PRIMEZONE) -- IBS has signed an agreement with R98, one of Denmark's largest waste management companies, for a value of SEK 16 million. The first stage of the order comprises the installation of an entirely new IT system with software and consultancy services.
Xenova Group PLC
Xenova Group PLC -- Tariquidar Phase I Paediatric Study Data Presented at ASCO
SLOUGH, U.K., June, 7 2004 (PRIMEZONE) -- Xenova Group plc (LSE:XEN) (Nasdaq:XNVA) announced today that the Paediatric Oncology Branch of the National Cancer Institute (NCI) in Bethesda, U.S., yesterday presented a poster at the American Society of Clinical Oncology (ASCO) conference in New Orleans, Louisiana on the paediatric Phase I clinical trial of tariquidar in children with solid tumours.
Galapagos Reports Success in Identification and Validation of Proprietary Drug Targets and Moves into Drug Discovery
MECHELEN, Belgium, June 7, 2004 (PRIMEZONE) -- Galapagos Genomics NV, Europe's leading target discovery company, announced today that it has identified, validated and filed patent applications on several novel drug targets in Alzheimer's disease, osteoporosis, osteoarthritis, rheumatoid arthritis and asthma. Galapagos has recently initiated small molecule drug development programs based on these proprietary targets. In order to expedite the building of chemistry programs around its target portfolio, Galapagos has recruited Dr. Philip Huxley as Senior Director of Drug Discovery. Galapagos uses its adenoviral based over-expression (FLeXSelect(TM)) and siRNA knock-down (SilenceSelect(TM)) collections to identify genes that modulate selected diseases in human cell models. In addition to applications in its core disease areas, Galapagos provides access to its discovery technology to a number of corporate partners. Galapagos delivers its partners validated targets that are drugable, disease modifying, and ready to be taken into small molecule screens.
Millicom International Cellular
Millicom International Cellular: Notice Of General Meeting Of Shareholders
BERTRANGE, Luxembourg, June 5, 2004 (PRIMEZONE) -- Millicom International Cellular S.A. ("Millicom") (Nasdaq:MICC) (Stockholmsborsen: MIC), today announces that, in consideration of the quorum required by law not having been reached at the annual general meeting of shareholders of MILLICOM INTERNATIONAL CELLULAR S.A. (the "Company") held on May 25, 2004 to consider and vote on the below agenda item, a second general meeting of shareholders of the Company will be held at the registered office of the Company on July 7, 2004 at 2.30 p.m. to consider and vote on the following resolution: